COMPANY PROFILE // THE 014 REPORT
Rezolute, Inc.
RZLT (Nasdaq) · Formerly: AntriaBio, Inc.; FITS MY STYLE INC
Assembled from 3 government sources in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- AmberGLEIF: the direct parent is not reported; reporting exception filed with reason NON_PUBLIC.
- AmberLEI 549300T05L48T72P2G08 registration status is LAPSED (last update 2023-08-04): the legal-entity record has not been renewed.
✓ SEC filings✓ LEI✓ State registrationpossible match✓ Lobbying registrationpossible match✗ SAM registration✗ IRS return✗ Website
No SAM registration, no IRS return, no website on record.
Rezolute, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in NV, based in Redwood City, CA; listed as RZLT (Nasdaq).[source] It has filed 68 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G, filed 2026-11-19.[source] 1 lobbying disclosure filing name a client with this company's exact name (possible match).[source] Its largest institutional holders on 13F filings are FEDERATED HERMES, INC., RA CAPITAL MANAGEMENT, L.P., BlackRock, Inc. (as of 2026-06-30).[source] Seraphix flags 2 items from these records: LEI 549300T05L48T72P2G08 registration status is LAPSED (last update 2023-08-04); GLEIF.[source]
- red0
- amber2
- info0
- FEDERATED HERMES, INC.$67.6M
- RA CAPITAL MANAGEMENT, L.P.$49.1M
- BlackRock, Inc.$40.1M
- Opaleye Management Inc.$32.8M
- Balyasny Asset Management L.P.$24.2M
- VANGUARD CAPITAL MANAGEMENT LLC$19.9M
- Siren, L.L.C.$17.3M
- JACOBS LEVY EQUITY MANAGEMENT, INC$13.3M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Elam Nevan C · CEO (Director,Officer) · latest Form 4 2026-03-04 · filing · LinkedIn search
- Evans Daron · CFO (Officer) · latest Form 4 2026-03-31 · filing · LinkedIn search
- Karnawat Sunil Ratilal · Chief Commercial Officer (Officer) · latest Form 4 2025-12-15 · filing · LinkedIn search
- ROBERTS BRIAN KENNETH · Chief Medical Officer (Officer) · latest Form 4 2026-03-04 · filing · LinkedIn search
- FAUCHET PHILIPPE · Director · latest Form 4 2025-11-21 · filing · LinkedIn search
- Harris Erik · Director · latest Form 4 2025-11-21 · filing · LinkedIn search
- Hogenhuis Wladimir · Director · latest Form 4 2025-12-17 · filing · LinkedIn search
- KREHER NERISSA · Director · latest Form 4 2025-11-21 · filing · LinkedIn search
- Kim Young-Jin · Director · latest Form 4 2025-11-21 · filing · LinkedIn search
- Labrucherie Gil M · Director · latest Form 4 2025-11-21 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001509261 | source |
| LEI | 549300T05L48T72P2G08 | source |
| EIN | 27-3440894 | source |
| LDA clientpossible match | 73938 | record |
| Business address (SEC) | 275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY, CA, 94065 | source |
Does not exist in the records we hold: UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2022-03-19 · in -1,707 days · LEI next renewal (549300T05L48T72P2G08)
- 2027-02-14 · in 86 days · Next 10-Q due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-09-28 · in 312 days · Next 10-K due (period ended 2027-06-30; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Savara Inc · Elam Nevan C
- Ultragenyx Pharmaceutical Inc. · Harris Erik
- Septerna, Inc. · Labrucherie Gil M
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-16 filing 8-K items 1.01,7.01,9.01 · SEC EDGAR
- 2026-11-16 filing 424B5 · SEC EDGAR
- 2026-11-13 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-11-13 filing FWP · SEC EDGAR
- 2026-11-13 filing 424B5 · SEC EDGAR
- 2026-11-10 filing EFFECT · SEC EDGAR
- 2026-11-05 filing S-3 · SEC EDGAR
- 2026-11-05 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-29 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-10-21 filing Proxy statement · SEC EDGAR
- 2026-10-15 filing DRS · SEC EDGAR
- 2026-10-14 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-10-07 filing PRE 14A · SEC EDGAR
- 2026-10-05 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-09-24 filing Annual report (10-K) · SEC EDGAR
- 2026-09-24 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-06-02 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-05-12 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-12 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-05-04 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-03-24 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-02-12 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-02-12 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-01-07 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2025-12-05 filing S-3ASR · SEC EDGAR
- 2025-11-21 filing S-8 · SEC EDGAR
- 2025-11-21 filing 8-K items 5.07,9.01 · SEC EDGAR
- 2025-11-21 insider First Form 3/4/5 on record for Harris Erik (Director) · SEC Forms 3/4/5
- 2025-11-12 filing 8-K items 7.01,9.01 · SEC EDGAR
170 earlier entries
- 2025-11-06 filing Quarterly report (10-Q)
- 2025-11-06 filing 8-K items 2.02,9.01
- 2025-10-21 officer change 8-K items 1.01,1.02,5.02
- 2025-10-07 filing Proxy statement
- 2025-09-17 filing Annual report (10-K)
- 2025-09-17 filing 8-K items 2.02,9.01
- 2025-09-02 filing 8-K items 7.01,9.01
- 2025-08-27 insider First Form 3/4/5 on record for Karnawat Sunil Ratilal (Chief Commercial Officer)
- 2025-08-20 officer change 8-K items 1.01,5.02,7.01,9.01
- 2025-08-08 filing EFFECT
- 2025-08-01 filing CORRESP
- 2025-07-24 filing UPLOAD
- 2025-07-18 filing 8-K items 7.01,9.01
- 2025-07-17 filing S-3
- 2025-06-13 officer change 8-K/A items 5.02
- 2025-06-13 filing 8-K items 3.02,8.01,9.01
- 2025-06-13 insider First Form 3/4/5 on record for KREHER NERISSA (Director)
- 2025-06-13 insider First Form 3/4/5 on record for Labrucherie Gil M (Director)
- 2025-06-12 insider First Form 3/4/5 on record for Elam Nevan C (CEO)
- 2025-06-12 insider First Form 3/4/5 on record for Evans Daron (CFO)
- 2025-06-12 insider First Form 3/4/5 on record for ROBERTS BRIAN KENNETH (Chief Medical Officer)
- 2025-06-12 insider First Form 3/4/5 on record for FAUCHET PHILIPPE (Director)
- 2025-06-12 insider First Form 3/4/5 on record for Kim Young-Jin (Director)
- 2025-05-13 filing Quarterly report (10-Q)
- 2025-05-13 filing 8-K items 2.02,9.01
- 2025-04-28 filing 8-K items 7.01,9.01
- 2025-04-23 filing 8-K items 1.01,3.02,7.01,8.01,9.01
- 2025-04-23 filing 424B5
- 2025-04-23 filing 424B5
- 2025-04-23 filing 8-K items 7.01,9.01
- 2025-04-01 insider First Form 3/4/5 on record for Hogenhuis Wladimir (Director)
- 2025-03-28 officer change 8-K items 5.02
- 2025-02-12 filing Quarterly report (10-Q)
- 2025-02-12 filing 8-K items 2.02,9.01
- 2025-02-04 filing 8-K items 7.01,9.01
- 2025-01-14 filing 8-K items 7.01,9.01
- 2025-01-07 filing 8-K items 7.01,9.01
- 2024-12-30 filing S-8
- 2024-12-10 filing 8-K items 5.03,5.07,9.01
- 2024-11-07 filing Quarterly report (10-Q)
- 2024-11-07 filing 8-K items 2.02,9.01
- 2024-10-21 filing DEFA14A
- 2024-10-21 filing Proxy statement
- 2024-10-10 filing PRE 14A
- 2024-09-19 filing Annual report (10-K)
- 2024-09-19 filing 8-K items 2.02,9.01
- 2024-09-09 filing 8-K items 7.01,9.01
- 2024-08-14 filing EFFECT
- 2024-08-13 filing CORRESP
- 2024-08-12 filing S-3/A
- 2024-08-09 filing UPLOAD
- 2024-08-05 filing S-3
- 2024-08-05 filing 8-K items 7.01,9.01
- 2024-06-28 filing 8-K items 7.01,9.01
- 2024-06-27 filing 8-K items 1.01,3.02,7.01,9.01
- 2024-06-14 filing 8-K items 1.01,7.01,9.01
- 2024-06-14 filing 424B5
- 2024-06-13 filing 424B5
- 2024-05-24 filing 8-K items 7.01,9.01
- 2024-05-17 filing 8-K items 5.07,9.01
- 2024-05-15 filing Quarterly report (10-Q)
- 2024-05-15 filing 8-K items 2.02,9.01
- 2024-04-25 filing 8-K items 7.01,9.01
- 2024-04-15 filing Proxy statement
- 2024-03-14 filing 8-K items 1.01,4.01,9.01
- 2024-03-11 filing 8-K items 7.01,9.01
- 2024-02-22 filing 8-K items 8.01,9.01
- 2024-02-13 filing Quarterly report (10-Q)
- 2024-02-13 filing 8-K items 2.02,9.01
- 2024-01-29 officer change 8-K items 3.02,5.02,7.01,9.01
- 2023-12-14 filing 8-K items 7.01,9.01
- 2023-11-29 filing EFFECT
- 2023-11-27 filing CORRESP
- 2023-11-22 filing S-3/A
- 2023-11-22 filing 8-K items 3.01,9.01
- 2023-11-20 filing UPLOAD
- 2023-11-14 filing S-3
- 2023-11-13 filing Quarterly report (10-Q)
- 2023-11-13 filing 8-K items 2.02,9.01
- 2023-10-18 filing 8-K items 7.01,9.01
- 2023-10-13 filing 8-K items 7.01,9.01
- 2023-09-14 filing Annual report (10-K)
- 2023-09-14 filing 8-K items 2.02,9.01
- 2023-06-27 filing 8-K items 7.01,8.01,9.01
- 2023-06-20 filing 8-K items 7.01
- 2023-06-02 filing 8-K items 5.05,9.01
- 2023-05-26 filing 8-K items 5.07,9.01
- 2023-05-11 filing Quarterly report (10-Q)
- 2023-05-11 filing 8-K items 2.02,9.01
- 2023-05-03 filing SC 13D/A
- 2023-04-12 filing DEFA14A
- 2023-04-12 filing Proxy statement
- 2023-02-10 filing Quarterly report (10-Q)
- 2023-02-10 filing 8-K items 2.02,9.01
- 2023-01-13 officer change 8-K items 5.02,9.01
- 2022-12-15 filing 8-K items 7.01,9.01
- 2022-11-09 filing EFFECT
- 2022-11-09 filing Quarterly report (10-Q)
- 2022-11-09 filing 8-K items 2.02,9.01
- 2022-11-07 filing CORRESP
- 2022-11-07 filing S-8
- 2022-11-04 filing UPLOAD
- 2022-10-28 filing S-3
- 2022-09-15 filing Annual report (10-K)
- 2022-09-15 filing 8-K items 2.02,9.01
- 2022-07-01 filing EFFECT
- 2022-07-01 filing 424B3
- 2022-07-01 filing 8-K items 1.02,2.04
- 2022-06-29 filing CORRESP
- 2022-06-28 filing S-3/A
- 2022-06-17 filing S-3
- 2022-06-17 filing 8-K items 5.03,5.07,8.01,9.01
- 2022-05-20 filing 424B5
- 2022-05-20 filing 424B5
- 2022-05-16 filing Proxy statement
- 2022-05-16 filing 8-K items 1.02
- 2022-05-12 filing Quarterly report (10-Q)
- 2022-05-12 filing 8-K items 2.02,9.01
- 2022-05-06 filing PRE 14A
- 2022-05-04 filing 8-K items 1.01,3.02,7.01,9.01
- 2022-05-02 filing 424B5
- 2022-05-02 filing 8-K items 7.01,8.01,9.01
- 2022-03-30 filing 8-K items 7.01,9.01
- 2022-03-23 filing 8-K items 7.01,9.01
- 2022-02-22 filing 8-K items 7.01,9.01
- 2022-02-09 filing Quarterly report (10-Q)
- 2022-02-09 filing 8-K items 2.02,9.01
- 2021-11-12 filing Quarterly report (10-Q)
- 2021-11-12 filing 8-K items 2.02,9.01
- 2021-10-19 filing 8-K items 7.01,9.01
- 2021-10-14 filing 424B5
- 2021-10-14 filing 424B5
- 2021-10-13 filing 8-K items 1.01,9.01
- 2021-10-12 filing 424B5
- 2021-09-27 filing 10-K/A
- 2021-09-23 filing 8-K items 7.01,9.01
- 2021-09-15 filing Annual report (10-K)
- 2021-09-15 filing 8-K items 2.02,9.01
- 2021-09-13 filing 8-K items 7.01,9.01
- 2021-08-11 filing 8-K items 7.01,9.01
- 2021-08-04 filing 8-K items 1.01,9.01
- 2021-08-04 filing 424B5
- 2021-07-28 filing SC 13D
- 2021-07-28 filing S-8
- 2021-06-28 filing 8-K items 8.01,9.01
- 2021-06-24 filing EFFECT
- 2021-06-23 filing EFFECT
- 2021-06-23 filing EFFECT
- 2021-06-23 filing EFFECT
- 2021-06-23 filing EFFECT
- 2021-06-23 filing EFFECT
- 2021-06-23 filing EFFECT
- 2021-06-23 filing EFFECT
- 2021-06-23 filing EFFECT
- 2021-06-21 filing POS AM
- 2021-06-21 filing POS AM
- 2021-06-21 filing POS AM
- 2021-06-21 filing POS AM
- 2021-06-21 filing POS AM
- 2021-06-21 filing POS AM
- 2021-06-21 filing POS AM
- 2021-06-21 filing POS AM
- 2021-06-21 filing POS AM
- 2021-06-21 filing 8-A12B/A
- 2021-06-21 officer change 8-K12B items 1.01,2.03,3.03,5.02,5.03,9.01
- 2021-06-02 filing 8-K items 5.07
- 2021-05-17 filing Quarterly report (10-Q)
- 2021-05-17 filing 8-K items 2.02,9.01
- 2021-05-04 filing 8-K items 8.01,9.01
- 2021-04-28 filing Proxy statement
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-16 (within 7 days) 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-16 (within 7 days) 424B5 filed
- 2026-11-13 (within 7 days) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-11-13 (within 7 days) FWP filed
- 2026-11-13 (within 7 days) 424B5 filed
- 2026-11-10 (within 30 days) EFFECT filed
- 2026-11-05 (within 30 days) S-3 filed
- 2026-11-05 (within 30 days) 10-Q filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-19; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:RZLT The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
2 possible matches held apart, matched by name only, not counted above; 5 records under a former name, shown apart.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1509261 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | RZLT / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 549300T05L48T72P2G08 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 549300T05L48T72P2G08) | GLEIF |
| EIN | 273440894 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001509261 | SEC EDGAR / IRS |
| CUSIP | 76200L309 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001509261 | SEC EDGAR |
possible match: matched by name only, not merged (1)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| LDA client id | 73938 (REZOLUTE, INC. (lobbying via LMH STRATEGIC SOLUTIONS)) | name-exact:legal-name: same registered legal name as 'Rezolute, Inc.' | Lobbying Disclosure Act (LDA) |
former name (shown apart, not merged) (5)
- former nameANTRIABIO, INC · State licences
- former nameANTRIABIO, INC. · State licences
- former nameANTRIABIO, INC. · State licences
- former nameANTRIABIO, INC. · State licences
- former nameANTRIABIO, INC. · State licences
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2026-06-30) | -$77,586,000 | 2026-06-30 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-19 22:39 UTC | Report an error |
| Total assets (at 2026-06-30) | $112,849,000 | 2026-06-30 | 10-K, XBRL Assets | as filed | 2026-11-19 22:39 UTC | Report an error |
| Stockholders' equity (at 2026-06-30) | $100,687,000 | 2026-06-30 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-19 22:39 UTC | Report an error |
| Cash and cash equivalents (at 2026-06-30) | $10,615,000 | 2026-06-30 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-19 22:39 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-19 22:39 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-19 22:39 UTC | Report an error |
| State of incorporation | NV | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-19 22:39 UTC | Report an error |
| Fiscal year end (MMDD) | 0630 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-19 22:39 UTC | Report an error |
| Business address | 275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY, CA, 94065 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-19 22:39 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-19 22:39 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2026-06-30) | -$64,635,000 | 2026-06-30 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-19 22:39 UTC | Report an error |
| Operating lease liabilities (at 2026-06-30) | $934,000 | 2026-06-30 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-19 22:39 UTC | Report an error |
| Form D total offering amount (D filed 2020-10-22) | $56,990,020 | 2020-10-22 | D | as filed | 2026-11-19 22:39 UTC | Report an error |
| Form D total amount sold (D filed 2020-10-22) | $41,000,000 | 2020-10-22 | D | as filed | 2026-11-19 22:39 UTC | Report an error |
| Form D industry group | Biotechnology | 2020-10-22 | D | as filed | 2026-11-19 22:39 UTC | Report an error |
| Form D revenue range | No Revenues | 2020-10-22 | D | as filed | 2026-11-19 22:39 UTC | Report an error |
| Form D date of first sale | 2020-10-09 | 2020-10-22 | D | as filed | 2026-11-19 22:39 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001104659-26-123364
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$18,487,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-05 | 0001104659-26-123364 | 2026-11-19 22:39 UTC | Report an error |
| Cash and cash equivalents | $8,150,000 | at 2026-09-30 | 10-Q | 2026-11-05 | 0001104659-26-123364 | 2026-11-19 22:39 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-16 Filing 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-16 Filing 424B5 filed
- 2026-11-13 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-11-13 Filing FWP filed
- 2026-11-13 Filing 424B5 filed
- 2026-11-10 Filing EFFECT filed
- 2026-11-05 Filing S-3 filed
- 2026-11-05 Filing 10-Q filed
- 2026-11-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-29 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-21 Filing DEF 14A filed
- 2026-10-15 Filing DRS filed
- 2026-10-14 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-07 Filing PRE 14A filed
- 2026-10-05 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-09-24 Filing 10-K filed
- 2026-09-24 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-06-02 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-05-12 Filing 10-Q filed
- 2026-05-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-05-04 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-03-24 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-02-12 Filing 10-Q filed
- 2026-02-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-01-07 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
8-K item text, as filed (excerpts)
- 2026-11-16 8-K Item 1.01, Entry into a Material Definitive Agreement
Underwriting Agreement On November 13, 2026, Rezolute, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters listed therein (the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”) by the Company of (i) 22,040,976 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an offering price of $3.8700 per share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 3,800,000 shares of Common Stock at an offering… the 8-K · retrieved 2026-11-19 22:39 UTC - 2026-11-16 8-K Item 7.01, Regulation FD Disclosure
Pricing Press Release On November 13, 2026, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached hereto as Exhibit 99.1. The information in Item 7.01 of this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for any purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such Section, and shall not be deemed to be incorporated by reference into any of the Company's filings under the Securities Act or the Exchange Act, whether made before or after the date… the 8-K · retrieved 2026-11-19 22:39 UTC - 2026-11-13 8-K Item 7.01
Regulation FD Disclosure. On November 13, 2026, Rezolute, Inc. (the “Company”) issued a press release to announce an interim update on its upLIFT study. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K. The… the 8-K · retrieved 2026-11-19 22:39 UTC - 2026-11-05 8-K Item 2.02
Results of Operations and Financial Condition. On November 5, 2026, Rezolute, Inc. issued a press release announcing its financial results for the first quarter ended September 30, 2026. A copy of this press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as… the 8-K · retrieved 2026-11-19 22:39 UTC - 2026-10-29 8-K Item 7.01
Regulation FD Disclosure. Rezolute, Inc. (the “Company”) prepared presentation materials (the “Investor Presentation”) that management released on its website on October 29, 2026. From time to time thereafter, the Company may use the Investor Presentation, possibly with modifications, in presentations to current and potential investors, analysts, lenders, business partners, acquisition candidates, customers, employees, and others with an interest in the Company and its business. A copy of the Investor Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for… the 8-K · retrieved 2026-11-19 22:39 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · NAME ONLY6. Lobbying (LDA)
1 lobbying record carry this company's exact name, hiring 1 lobbying firm. These are possible matches until the accuracy score, so they are not counted in the headline.
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchREZOLUTE, INC. (lobbying via LMH STRATEGIC SOLUTIONS) · exact legal name · sx:lda:73938 Compare
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | FEDERATED HERMES, INC. | $67,551,427 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
| 2 | RA CAPITAL MANAGEMENT, L.P. | $49,114,203 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
| 3 | BlackRock, Inc. | $40,135,113 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
| 4 | Opaleye Management Inc. | $32,760,000 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
| 5 | Balyasny Asset Management L.P. | $24,242,603 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | $19,946,300 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
| 7 | Siren, L.L.C. | $17,307,092 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
| 8 | JACOBS LEVY EQUITY MANAGEMENT, INC | $13,320,601 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
| 9 | JENNISON ASSOCIATES LLC | $12,788,402 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | $11,288,227 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- REZOLUTE, INC. · LEI 549300T05L48T72P2G08 · root
Exhibit 21 subsidiaries: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
1 state and city record carry this company's exact name, from 1 source. Possible matches only.
State licences (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchREZOLUTE, INC. · exact legal name · sx:elic:ctcred:1752936 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1509261.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001509261. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.